Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

3 min

161 shares, 222 points

In a recent study published in the International Journal of Molecular Sciences, researchers identified drugs inhibiting the entry of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Study: Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. Image Credit:


SARS-CoV-2 enters host cells by attaching to the angiotensin-converting enzyme 2 (ACE2) receptor through its spike (S) protein. Blocking the interactions between ACE2 and S protein is critical to inhibiting infection. Coronavirus disease 2019 (COVID-19) vaccination has been (mostly) effective in curtailing the infection outbreak. Nevertheless, several variants of concern (VOCs) have emerged, exhibiting significant resistance to the vaccine- or infection-induced immunity. Hence, there is a pressing need to develop broad-spectrum drugs which inhibit the wild-type strain and mutant variants of SARS-CoV-2.

The study and findings

In the present study, researchers developed an assay for detecting the molecular interactions between the S protein’s receptor-binding domain (RBD) and the ACE2 receptor. A drug library was screened to identify potential (entry) inhibitors.

The authors employed the protein complementation technology, i.e., NanoLuc binary technology (NanoBiT), to develop the ACE2-RBD attachment assay. The human ACE2 was fused with the Small BiT (SmBiT) subunit of NanoLuc luciferase, transfected into HeLa cells, and a stable HeLa cell line expressing SmBiT-ACE2 was established. Subsequently, five large BiT (LgBiT)-RBD or S1 subunit fusion constructs were generated.

The recombinant fusion products (LgBiT-RBD, LgBiT-S1) were incubated with the cells expressing SmBiT-ACE2. No luminescence was detected with LgBiT-RBD, LgBiT-S1, and S1-LgBiT fusion constructs, while a robust luminescence signal was observed for the RBD-LgBiT construct. Another (fusion) construct with a linker between RBD and LgBiT (RBD-linker-LgBiT) had no noticeable improvements in the luciferase activity, and subsequent experiments were performed using the RBD-LgBiT construct.

Next, a Food and Drug Administration (FDA)-approved drug library was screened to identify potential drug candidates with inhibitory effects on the attachment of SARS-CoV-2 RBD. Of the 1068 drugs, 16 demonstrated RBD attachment inhibition by over 50%. Negative screening of the top 20 drugs with the highest inhibitory activity using the HiBiT-NanoLuc assay eliminated 11 candidates from further analysis. The nine candidates were Aripiprazole, ABT-199, Dolutegravir Sodium, Etravirine, Gramicidin, Ivermectin, Miconazole, Miconazole Nitrate, and Ospemifene.

A cytotoxic assay was performed on VeroE6 cells using these (nine) candidates, and only three: Dolutegravir, Etravirine, and Sspemifene, were non-toxic. Further, the candidate drugs were subject to the RBD-ACE2 attachment assay, which found Etravirine as the most effective, with a half-maximal effective concentration (EC50) of 2.3 µM. Ivermectin which inhibits SARS-CoV-2 replication in cell cultures exhibited a weak EC50 of 22.8 µM.

Pseudoviruses with SARS-CoV-2 S protein and NanoLuc reporter gene were produced. SmBiT-ACE2 cells were incubated with pseudovirus and candidate inhibitors for six hours, followed by the removal of pseudovirus and continued incubation for 16 hours. Dolutegravir and Etravirine neutralized S-typed pseudoviruses with EC50 values of 40 nM and 5.8 nM, respectively. The neutralization efficiency of the candidates was determined using the plaque reduction neutralization test (PRNT).

The (authentic) SARS-CoV-2 was pre-incubated with the candidate drugs before infecting VeroE6 cells. Neutralization was estimated by quantitating the plaques five days-post infection (dpi). Dolutegravir neutralized SARS-CoV-2 infection with an EC50 of 4.2 µM and Etravirine at 7.7 µM, whereas ivermectin inhibited 60% of infection; the authors presumed that the result might have been biased due to its cytotoxicity.

Molecular docking of Dolutegravir, Etravirine, and Ivermectin on S RBD and ACE2 was carried out. With ACE2-inhibitor(s) docking, the predictive binding sites were not at the RBD interaction interphase, indicating that it was not the primary target of the inhibitors. Unsurprisingly, high affinity was detected between S RBD and inhibitors at the ACE2-S protein interphase. The mean affinity score of Dolutegravir to RBD was -7.52 kilocalories per mole (kcal/mol), and it was -7.8 kcal/mol for Etravirine.

Moreover, when S RBD harboring N501Y substitution was tested, docking results were unaffected. The researchers investigated the neutralization potential of Dolutegravir and Etravirine against pseudoviruses carrying the S protein of Alpha, Beta, Delta, or Omicron VOCs. No significant changes were noted in the EC50 values of the two drugs against SARS-CoV-2 VOCs. Of note was the highly potent neutralization of the Omicron VOC by both the drugs.


The research team identified two potent drugs for inhibiting the entry of SARS-CoV-2 into host cells. Overall, the RBD-ACE2 attachment developed by the researchers is robust and offers attachment results in just 10 minutes without the need for biosafety level (BSL)-2 facilities. The two drugs were effective and inhibited wild-type virus and mutant variants. Since the drugs can be administered orally, the authors posit their use as pre-or post-exposure prophylactic COVID-19 treatment.

Source: News Medical

Like it? Share with your friends!

161 shares, 222 points

What's Your Reaction?

Cute Cute
Fun Fun
Hate Hate
Confused Confused
Fail Fail
Geeky Geeky
Love Love
Choose A Format
Personality quiz
Series of questions that intends to reveal something about the personality
Trivia quiz
Series of questions with right and wrong answers that intends to check knowledge
Voting to make decisions or determine opinions
Formatted Text with Embeds and Visuals
The Classic Internet Listicles
The Classic Internet Countdowns
Open List
Submit your own item and vote up for the best submission
Ranked List
Upvote or downvote to decide the best list item
Upload your own images to make custom memes
Youtube, Vimeo or Vine Embeds
Soundcloud or Mixcloud Embeds
Photo or GIF
GIF format